HomeCompareBACHF vs PFE

BACHF vs PFE: Dividend Comparison 2026

BACHF yields 5.05% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BACHF wins by $129.75M in total portfolio value
10 years
BACHF
BACHF
● Live price
5.05%
Share price
$0.64
Annual div
$0.03
5Y div CAGR
80.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$129.80M
Annual income
$117,169,505.33
Full BACHF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — BACHF vs PFE

📍 BACHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBACHFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BACHF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BACHF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BACHF
Annual income on $10K today (after 15% tax)
$429.55/yr
After 10yr DRIP, annual income (after tax)
$99,594,079.53/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, BACHF beats the other by $99,571,759.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BACHF + PFE for your $10,000?

BACHF: 50%PFE: 50%
100% PFE50/50100% BACHF
Portfolio after 10yr
$64.93M
Annual income
$58,597,882.02/yr
Blended yield
90.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

BACHF
No analyst data
Altman Z
-0.7
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BACHF buys
0
PFE buys
0
No recent congressional trades found for BACHF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBACHFPFE
Forward yield5.05%6.13%
Annual dividend / share$0.03$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR80.2%13.2%
Portfolio after 10y$129.80M$49.6K
Annual income after 10y$117,169,505.33$26,258.71
Total dividends collected$128.80M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BACHF vs PFE ($10,000, DRIP)

YearBACHF PortfolioBACHF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,611$910.64$9,153$693.39+$2.5KBACHF
2$14,204$1,780.64$8,593$849.25+$5.6KBACHF
3$18,867$3,668.61$8,336$1,066.78+$10.5KBACHF
4$28,394$8,206.59$8,437$1,384.80+$20.0KBACHF
5$51,182$20,799.93$9,013$1,875.40+$42.2KBACHF
6$117,906$63,142.00$10,306$2,680.72+$107.6KBACHF
7$371,129$244,969.47$12,820$4,101.38+$358.3KBACHF
8$1,695,695$1,298,586.14$17,673$6,826.70+$1.68MBACHF
9$11,806,662$9,992,268.45$27,543$12,591.86+$11.78MBACHF
10$129,802,633$117,169,505.33$49,560$26,258.71+$129.75MBACHF

BACHF vs PFE: Complete Analysis 2026

BACHFStock

Bank of China Limited, together with its subsidiaries, provides various banking and financial services. It operates through six segments: Corporate Banking, Personal Banking, Treasury Operations, Investment Banking, Insurance, and Other Operations. The Corporate Banking segment offers current accounts, deposits, overdrafts, loans, trade-related products and other credit facilities, foreign currency, derivatives, and wealth management products to corporate customers, government authorities, and financial institutions. The Personal Banking segment provides savings deposits, personal loans, credit and debit cards, payments and settlements, wealth management products, and funds and insurance agency services to retail customers. The Treasury Operations segment is involved in foreign exchange transactions, customer-based interest rate and foreign exchange derivative transactions, money market transactions, proprietary trading, and asset and liability management. The Investment Banking segment offers debt and equity underwriting, financial advisory, stock brokerage, investment research and asset management, and private equity investment services, as well as sells and trades in securities. The Insurance segment underwrites general and life insurance products; and provides insurance agency services. As of December 31, 2021, the company had 10,382 branches and outlets, which include 520 institutions in the Chinese mainland and 550 institutions in Hong Kong, Macao, Taiwan, and other countries. It is also involved in the aircraft leasing business. The company was founded in 1912 and is headquartered in Beijing, China.

Full BACHF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this BACHF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BACHF vs SCHDBACHF vs JEPIBACHF vs OBACHF vs KOBACHF vs MAINBACHF vs JNJBACHF vs MRKBACHF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.